Drugs / APNmAb005
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05344989 Comparator | May 2022 → Mar 2024 | Alzheimer disease | APRINOIA Therapeutics, LLC | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-12-10 | APRINOIA Therapeutics, LLC | APRINOIA Therapeutics Reported a Novel Oligomer Tau Assay System with APNmAb005 Antibody, Successfully Detected the Target Molecule of Oligomer Tau Species and Elucidated the Increases Depending on Disease Progression of Alzheimer’s Disease aprinoia.com ↗ |
| 2022-04-11 | APRINOIA Therapeutics, LLC | APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial aprinoia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APNmAb005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05344989 ↗ |
| Route | Intravenous | “Administered by IV infusion” NCT05344989 ↗ |